<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042856</url>
  </required_header>
  <id_info>
    <org_study_id>ZYY-PanOptix IOL</org_study_id>
    <nct_id>NCT05042856</nct_id>
  </id_info>
  <brief_title>To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients</brief_title>
  <official_title>A Prospective, Single Center Study to Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate IOL position, clinical outcome of PanOptix in high myopic cataract patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single center study to evaluate IOL position, clinical outcome of PanOptix in&#xD;
      high myopic cataract patients.&#xD;
&#xD;
      The objective of this study to investigate the refractive and visual performance of PanOptix&#xD;
      and explore their correlation with ELP change, capsular bending formation, IOL&#xD;
      tilt/decentration in high myopic cataract patients.&#xD;
&#xD;
      PanOptix IOL provides good refractive outcomes and visual quality because of few ELP change,&#xD;
      fast capsular bending formation and few tilt and decentration in high myopic cataract&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective Lens Position（ELP）</measure>
    <time_frame>3 months</time_frame>
    <description>Mean change of ELP for 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>capsule bending index（CBI）</measure>
    <time_frame>3months</time_frame>
    <description>Post-op 1 day，1week，1month，and 3 months monocular CBI(Swept source OCT,Casia SS-1000; Tomey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lOL tilt</measure>
    <time_frame>3 months</time_frame>
    <description>Post-op 1 day ,1 week,1 month and 3 months lOL tilt(Swept source OCT,Casia SS-1000; Tomey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lOL decentration</measure>
    <time_frame>3 months</time_frame>
    <description>Post-op 1 day ,1 week,1 month and 3 months lOL decentration(Swept source OCT,Casia SS-1000; Tomey)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular uncorrected distance visual acuity（UDVA）</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months Monocular UDVA(Chinese standard logarithmic charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular best corrected distance visual acuity（BCDVA）(5m)</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months Monocular BCDVA(5m)(Chinese standard logarithmic charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular uncorrected intermediate visual acuity（UIVA）</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months Monocular UIVA(Chinese standard logarithmic charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular distance corrected intermediate visual acuity(DCIVA)(60cm)</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months Monocular DCIVA(60cm)(Chinese standard logarithmic charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular uncorrected near visual acuity（UNVA）</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months Monocular UNVA(Chinese standard logarithmic charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular distance corrected near visual acuity(DCNVA)(40cm)</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months Monocular DCNVA(40cm)(Chinese standard logarithmic charts)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>manifest refraction</measure>
    <time_frame>3 months</time_frame>
    <description>Pre-op and post-op 1 day,1 week,1 month and 3 months manifest refraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocular defocus curve</measure>
    <time_frame>3 months</time_frame>
    <description>Post-op 1month,3 months monocular defocus curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modulation transfer function（MTF）</measure>
    <time_frame>3 months</time_frame>
    <description>Post-op 1 day,1 week,1 month and 3 months MTF(OPD-Scan III Analyzer,NIDEK CO.,LTD.,Tokyo,Japan)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-order aberrations（HOA）</measure>
    <time_frame>3 months</time_frame>
    <description>Post-op 1 day,1 week,1 month and 3 months HOA(OPD-Scan III Analyzer,NIDEK CO.,LTD.,Tokyo,Japan)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cataract</condition>
  <condition>High Myopia</condition>
  <arm_group>
    <arm_group_label>PanOptix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PanOptix IOL implantation</intervention_name>
    <description>All the patients will be bilaterally implanted with PanOptix IOL，one eye will be randomized selected for monocular analysis of each patient.</description>
    <arm_group_label>PanOptix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  26 ≤Axial length&lt;30mm, IOL power ≥6D (PanOptix IOL power is available +6D-+30D )&#xD;
&#xD;
          -  Eyes with corneal astigmatism less than 1.0D (IOLMaster 700, Carl Zeiss Meditec AG)&#xD;
&#xD;
          -  Eyes with pupil diameter between 3 and 5.5 mm (iTrace, Tracey Technology, Houston,&#xD;
             Texas, USA)&#xD;
&#xD;
          -  Eyes with angle kappa and angle Alpha ≤0.50 mm (iTrace);&#xD;
&#xD;
          -  Eyes with corneal spherical aberration ≤ 0.50 (Pentacam).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Irregular corneal astigmatism&#xD;
&#xD;
          -  Serious intraoperative complications, glaucoma, pseudoexfoliation syndrome, uveitis,&#xD;
             macular degeneration or other retinal impairment&#xD;
&#xD;
          -  Moderate-severe dry eye, corneal scarring, amblyopia&#xD;
&#xD;
          -  Patients who can't cooperate with post-op 3 months follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yune zhao, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yinying zhao</last_name>
    <phone>+86 13957763247</phone>
    <email>ginger146@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmology and Optometry Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>zhao yun-e</last_name>
      <phone>+86 13819707056</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>Yune Zhao</investigator_full_name>
    <investigator_title>Vice president of Eye Hospital of Wenzhou Medical University</investigator_title>
  </responsible_party>
  <keyword>PanOptix IOL</keyword>
  <keyword>high myopic cataract patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

